# Brexanolone phase 3 trials report, Lancet 2018

Publication · id `maternal:pub-brexanolone-lancet-2018` · Maternal & Newborn Atlas · release `c7fb95f1d15a7d13` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

Browse, life stage: Postpartum  
Browse, care area: Mental health  

## In plain language

The report of the two phase 3 trials of brexanolone injection for postpartum depression, published in The Lancet in 2018.

## Technical summary

Lancet 2018;392(10152):1058-1070. doi:10.1016/S0140-6736(18)31551-4. PMID 30177236.

## Connected pages

- Published in: The Lancet (`core:lancet`)

## Provenance

Content hash: 9c32e69eee1dd60c263695f1fe9ad19532a0c50bf2ef8435cf982c22d693bbe1
Last substantive edit: 2026-10-15
Evidence last checked: Not recorded